

# MAYO CLINIC

**CLINIC** Exhibitor & Sponsorship Prospectus

Mayo Clinic Updates in Lymphoid Malignancies 2025: Best of Lugano The Ritz Carlton Lake Tahoe October 9-11, 2025

#### Welcome -

On behalf of the course directors Grzegorz S. Nowakowski, M.D. and Emanuele Zucca, M.D. and Mayo Clinic School of Continuous Professional Development, we are pleased to announce the upcoming **Mayo Clinic Updates in Lymphoid Malignancies 2025: Best of Lugano** course being held at the Ritz Carlton Lake Tahoe, Truckee, CA.

This interactive course is designed to provide attendees with up-to-date, practical information and best practices that can be applied immediately into daily clinical practice. Each session will focus on a specific subtype of lymphoid neoplasia, highlighting the most exciting data from ICML. Mayo Clinic experts will be joined by lymphoma experts from the international community to provide further content and enhance learning through incorporating multidisciplinary expertise, including Hematopathology and Radiation Oncology.

Please visit the course website at <a href="mayo.edu/lymphoid2025">ce.mayo.edu/lymphoid2025</a> for additional details on the course. The Updates in Lymphoid Malignances 2025: Best of Lugano will be held at the Ritz Carlton Lake Tahoe. Guest rooms have been reserved at a discounted rate over the course dates. Room reservations can be made before September 17, 2025, or before the room block fills.

#### The Ritz Carlton Lake Tahoe

13031 Ritz-Carlton Highlands Court Truckee, CA 96161 +1 (530) 562-3000

If you are interested in participating in this course, please complete the electronic Letter of Agreement Form. If you have not already done so, please <u>create an account</u> prior to signing our letter of agreement.

Mayo Clinic recognizes these types of educational programs would not be possible without your support. We have a variety of sponsorship opportunities for you to consider. If you do not see what you are looking for, contact us and we will be happy to discuss additional advertisement opportunities.

Thank you for your consideration!

# Mayo Clinic Updates in Lymphoid Malignancies 2025: Best of Lugano

#### **Overview:**

This course offers a quality selection of marketing and advertising opportunities. These are designed to help companies further engage, network and connect with attendees during the annual conference. Mayo Clinic staff can help maximize exposure through additional advertisement opportunities.

## Why Sponsor:

Technical and educational exhibits provide a professional and educational environment in which physicians can receive demonstrations, view products and services and discuss the clinical and surgical uses of these products and services, including how they may improve the quality of care and the management of the medical/surgical practice. Additionally, the exhibits enhance the educational content of the meeting helping to provide quality continuing medical education.

Benefits of Sponsorship:

- Interact face-to-face with numerous medical professionals
- Build visibility for your company in a competitive marketplace
- Expand your customer base and strengthen existing customer relationships
- Introduce new products and services
- Additional advertisement opportunities to expand reach and further socialize with attendees Sponsorships opportunities

# **Sponsorship Opportunities**

### Platinum Level - \$50,000.00

- Premium exhibit location
- Two 6-foot exhibit tables
- Recognition in conference syllabus, signage, break slides & announcement from podium.
- Attendee list (Opt-in only name, city, and state)
- Complimentary registration for four representatives

#### **Gold Level** - \$30,000.00

- Premium exhibit location
- One 6-foot exhibit table
- Recognition in conference syllabus, signage, break slides & announcement from podium.
- Attendee list (Opt-in only name, city, and state
- Complimentary registration for three representatives

### **Silver Level** - \$15,000.00

- One 6-foot exhibit table
- Recognition in conference syllabus, signage, break slides & announcement from podium.
- Attendee list (Opt-in only name, city, and state)
- Complimentary registration for two representatives

#### Product Theatre - \$40,000.00

Showcase your product offerings to attendees with a product theatre.

- 60-minute luncheon session with complimentary meeting room space. Food and beverage will be
  provided by Mayo Clinic. Attendee list after the event, networking opportunities, and
  acknowledgment and recognition at the conference
- Sponsor is responsible for providing speaker(s), program invitations and advertisements for the product theatre.
- Sponsor is logistically and financially responsible for any/all audiovisual needs for the product theatre.

#### Internet - \$15,000.00 (Exclusive)

Help attendees stay connected with their office and home while away at the conference. Sponsor wireless internet access in the meeting space for the course attendees.

- Supporter will be recognized throughout the meeting in signage and electronic communications.
- Company name will be displayed outside the meeting space.

# Power Sponsorship - \$10,000.00 (Exclusive)

Help attendees stay connected and engaged while attending the course. Sponsor the power in the meeting space for course attendees.

- Supporter will be recognized throughout the meeting in signage and electronic communications.
- Company name will be displayed outside the meeting space.

## Attendee Bags - \$7,500.00 (Exclusive)

Prominently display your company name on attendee bags. Sponsor is responsible for sourcing the bags and providing to the CME staff to distribute to attendees once onsite at the course.

- Supporter will be recognized throughout the meeting in signage and electronic communications.
- Company name will be displayed outside the meeting space.

## Click here to secure your Sponsorship

A signed letter of agreement is required to secure your Sponsorship.

This is a competitive course. Please consider signing our agreement early to secure Sponsorship.

Set-up: Wednesday, October 8th - Time TBD

Tear Down: Saturday October 11<sup>th</sup> – at conclusion of course

#### **Exhibit Hours:**

Thursday, October 9<sup>th</sup> 10:00 am to Saturday, September 13<sup>th</sup> 1:00 pm

# Payment – Sponsorship Only:

**PREFERRED Payment: Credit card** 

To pay by credit card, please click here

By Check: Make checks payable to:

**Mayo Clinic - MCSCPD** 

200 First St SW

Plummer 2-60, Attn: Morgan Gish

Rochester, MN 55905

Reference: Lymphoid Malignancies 5325R02228 on check

Mayo Clinic Tax ID: 41-6011702

# **Exhibit Opportunities**

# In-Person Exhibit Opportunity - \$5,000.00

- In-person exhibit tables are available on a first-come, first-serve basis.
- 6' table and (2) chairs
- Acknowledgement in announcements, signage, and at break slides
- Receive attendee list (name, credentials, city, state)
- Access to networking opportunities throughout the course

# Click here to secure your exhibit table

A signed letter of agreement is required to secure your exhibit table.

This is a competitive course. Please consider signing our agreement early to secure your table.

Set-up: Wednesday, October 8th - Time TBD

Tear Down: Saturday October 11<sup>th</sup> – at conclusion of course

#### **Exhibit Hours:**

Thursday, October 9th 10:00 am to Saturday, September 13th 1:00 pm

# Payment - Exhibit Only:

PREFERRED Payment: Credit card

To pay by credit card, please click here

By Check: Make checks payable to:

**Mayo Clinic - MCSCPD** 

200 First St SW

Plummer 2-60, Attn: Morgan Gish

Rochester, MN 55905

Reference: Lymphoid Malignancies 5325R02228 on check

Mayo Clinic Tax ID: 41-6011702

# Mayo Clinic Updates in Lymphoid Malignancies 2025: Best of Lugano




Ritz Carlton Lake Tahoe October 9-11, 2025 Pacific Time Zone

|            | Thursday, October 9, 2025   |  |  |  |  |  |  |  |
|------------|---|--|--|--|--|--|--|--|
|            | 111d13ddy, Getobel 3, 2023  |  |  |  |  |  |  |  |
| 10:00 a.m. | Registration  |  |  |  |  |  |  |  |
| 11:30 a.m. | Industry Sponsored Symposium (No CME)   |  |  |  |  |  |  |  |
| 12:30 p.m. | Networking Break  |  |  |  |  |  |  |  |
| 1:00 p.m.  | Opening Remarks   |  |  |  |  |  |  |  |
|            | Grzegorz S. Nowakowski, M.D., Emanuele Zucca, M.D.                                  |  |  |  |  |  |  |  |
|            | Hodgkin Lymphoma  |  |  |  |  |  |  |  |
| 1:15 p.m.  | Tumor Board Style Case  |  |  |  |  |  |  |  |
| ·          | Early Career Investigator, Radiation Oncologist, Hematopathologist                  |  |  |  |  |  |  |  |
|            | Current Landscape   |  |  |  |  |  |  |  |
|            | Early Career Investigator   |  |  |  |  |  |  |  |
| 1:30 a.m.  | Key Studies From 18-ICML  |  |  |  |  |  |  |  |
|            | Peter Borchmann, M.D.   |  |  |  |  |  |  |  |
|            | University of Hospital Cologne, Germany   |  |  |  |  |  |  |  |
| 1:45 p.m.  | Panel Discussion  |  |  |  |  |  |  |  |
| ·          | Peter Borchmann, M.D., Stephen M. Ansell, M.D., Ph.D Early Career Investigator,     |  |  |  |  |  |  |  |
|            | Radiation Oncologist, Radiologist   |  |  |  |  |  |  |  |
| 2:00 p.m.  | Case Resolution, Practice Changes, Anticipated Studies/Future Directions            |  |  |  |  |  |  |  |
| •          | Stephen M. Ansell, M.D., Ph.D   |  |  |  |  |  |  |  |
|            | T-cell Lymphoma   |  |  |  |  |  |  |  |
| 2:15 p.m.  | Tumor Board Style Case  |  |  |  |  |  |  |  |
|            | Early Career Investigator, Radiation Oncologist, Rebecca L. King, M.D.,             |  |  |  |  |  |  |  |
|            | Current Landscape   |  |  |  |  |  |  |  |
|            | Early Career Investigator   |  |  |  |  |  |  |  |
| 2:30 p.m.  | Key Studies From 18-ICML  |  |  |  |  |  |  |  |
| 2:45 p.m.  | Panel Discussion  |  |  |  |  |  |  |  |
|            | N. Nora Bennani, M.D., Rebecca L. King, M.D., Early Career Investigator             |  |  |  |  |  |  |  |
| 3:00 p.m.  | Case Resolution, Practice Changes, Anticipated Studies/Future Directions            |  |  |  |  |  |  |  |
|            | N. Nora Bennani, M.D.   |  |  |  |  |  |  |  |
| 3:15 p.m.  | Break / Open Discussion   |  |  |  |  |  |  |  |
|            | Diffuse Large B-cell Lymphoma and High-Grade Lymphomas                              |  |  |  |  |  |  |  |
| 3:30 p.m.  | Tumor Board Style Case  |  |  |  |  |  |  |  |
|            | Early Career Investigator, Radiation Oncologist, Eric D. Hsi, M.D.,                 |  |  |  |  |  |  |  |
|            | Current Landscape   |  |  |  |  |  |  |  |
|            | Early Career Investigator   |  |  |  |  |  |  |  |
| 3:45 p.m.  | Key Studies From 18-ICML  |  |  |  |  |  |  |  |
|            | Catherine Thieblemont, M.D., Ph.D.  |  |  |  |  |  |  |  |
| 4:15 p.m.  | Panel Discussion  |  |  |  |  |  |  |  |
|            | Grzegorz S. Nowakowski, M.D., Eric D. Hsi, M.D., Catherine Thieblemont, M.D., Ph.D. |  |  |  |  |  |  |  |
|            | Early Career Investigator, Radiation Oncologist, Radiologist                        |  |  |  |  |  |  |  |
| 4:30 p.m.  | m. Case Resolution, Practice changes, Anticipated Studies/Future Directions         |  |  |  |  |  |  |  |
|            | Grzegorz S. Nowakowski, M.D.  |  |  |  |  |  |  |  |
| 4:45 p.m.  | Poster Reception  |  |  |  |  |  |  |  |

| 5:45 p.m.     | Adjourn |  |
|---------------|---------|--|
| 1.3.43 D.III. | Adiourn |  |

|              | Friday, October 10, 2025  |  |  |  |  |  |
|--------------|---|--|--|--|--|--|
| 8:00 a.m.    | Industry Spansared Symposium Prophfact (NO CME)                                     |  |  |  |  |  |
|              | Industry Sponsored Symposium Breakfast (NO CME)                                     |  |  |  |  |  |
| 8:45 a.m.    | Networking Break  |  |  |  |  |  |
| 0.00         | Radiotherapy for Indolent NHL   |  |  |  |  |  |
| 9:00 a.m.    | Radiotherapy for Indolent NHL   |  |  |  |  |  |
|              | Follicular Lymphoma   |  |  |  |  |  |
| 9:30 a.m.    | Tumor Board Style Case  |  |  |  |  |  |
|              | Early Career Investigator, Radiation Oncologist, Radiologist, Ellen McPhail, M.D.,  |  |  |  |  |  |
|              | Current disease landscape   |  |  |  |  |  |
|              | Early Career Investigator   |  |  |  |  |  |
| 9:45 a.m.    | Key Studies From 18-ICML  |  |  |  |  |  |
|              | J.C. Villasboas-Bisneto, M.D.   |  |  |  |  |  |
| 10:00 a.m.   | Panel Discussion  |  |  |  |  |  |
|              | Ellen McPhail, M.D., J.C. C. Villasboas-Bisneto, M.D., Pier Luigi Zinzani           |  |  |  |  |  |
|              | Early Career Investigator, Radiation Oncologist, Radiologist                        |  |  |  |  |  |
| 10:15 a.m.   | Case Resolution, Practice changes, Anticipated Studies/Future Directions            |  |  |  |  |  |
|              | Pier Luigi Zinzani  |  |  |  |  |  |
|              | University of Bologna, Italy  |  |  |  |  |  |
|              | Indolent, Non-Follicular Lymphoma   |  |  |  |  |  |
| 10:30 a.m.   | Tumor Board Style Case  |  |  |  |  |  |
|              | Early Career Investigator, Radiation Oncologist, Rebecca L. King, M.D., Radiologist |  |  |  |  |  |
|              | Current Disease Landscape   |  |  |  |  |  |
|              | Early Career Investigator   |  |  |  |  |  |
| 10:45 a.m.   | Key Studies From 18-ICML  |  |  |  |  |  |
|              | Thomas M. Habermann, M.D.   |  |  |  |  |  |
| 11:00 a.m.   | Panel Discussion  |  |  |  |  |  |
|              | Thomas M. Habermann, M.D., Rebecca L. King, M.D., Emanuele Zucca, M.D., Early       |  |  |  |  |  |
|              | Career Investigator   |  |  |  |  |  |
| 11:15 a.m.   | Case Resolution, Practice changes, Anticipated Studies/Future Directions            |  |  |  |  |  |
|              | Emanuele Zucca, M.D.  |  |  |  |  |  |
| 11:30 a.m.   | Break / Open Discussion   |  |  |  |  |  |
|              | CLL and Richter Transformation  |  |  |  |  |  |
| 11:45 a.m.   | Tumor Board Style Case  |  |  |  |  |  |
|              | Early Career Investigator, Rebecca L. King, M.D., M.D., Ph.D., Radiologist          |  |  |  |  |  |
|              | Current disease landscape   |  |  |  |  |  |
|              | Early Career Investigator   |  |  |  |  |  |
| 12:00 p.m.   | Key Studies from 18-ICML  |  |  |  |  |  |
|              | Davide Rossi, M.D., Ph.D. (Richter Transformation)                                  |  |  |  |  |  |
|              | Institute of Southern Switzerland   |  |  |  |  |  |
|              | Sameer A. Parikh, M.B.B.S. (CLL)  |  |  |  |  |  |
| 12:30 p.m.   | Panel discussion  |  |  |  |  |  |
| P            | Rebecca L. King, M.D., Sameer A. Parikh, M.B.B.S, Davide Rossi, Early Career        |  |  |  |  |  |
|              | Investigator, Radiologist   |  |  |  |  |  |
| 12:45 p.m.   | Case Resolution, Practice changes, Anticipated Studies/Future Directions            |  |  |  |  |  |
| 12.75 p.iii. | Sameer A. Parikh, M.B.B.S.  |  |  |  |  |  |
| 1:00 p.m.    | "Meet the Professor" Lunch for Early Career Investigators                           |  |  |  |  |  |
| 2:00 p.m.    | Adjourn   |  |  |  |  |  |
| 2.00 p.111.  | Aujourii  |  |  |  |  |  |

| Saturday, October 11, 2025 |  |  |  |  |  |  |  |  |
|----------------------------|--|--|--|--|--|--|--|--|
| 7:30 a.m.                  | Breakfast Industry Sponsored Symposium (No CME) BEIGENE                              |  |  |  |  |  |  |  |
| 8:30 a.m.                  | Break / Open Discussion  |  |  |  |  |  |  |  |
| Mantle Cell Lymphoma       |  |  |  |  |  |  |  |  |
| 8:45 a.m.                  | Tumor Board Style Case   |  |  |  |  |  |  |  |
|                            | Early Career Investigator  |  |  |  |  |  |  |  |
|                            | Current Disease Landscape  |  |  |  |  |  |  |  |
|                            | Early Career Investigator  |  |  |  |  |  |  |  |
| 9:00 a.m.                  | Key Studies From 18-ICML   |  |  |  |  |  |  |  |
|                            | Luhua (Michael) Wang, M.D. MD Anderson Cancer Center                                 |  |  |  |  |  |  |  |
| 9:15 a.m.                  | Panel Discussion   |  |  |  |  |  |  |  |
|                            | Javier L. Munoz, M.D., M.B.A., Luhua (Michael) Wang, M.D., Early Career Investigator |  |  |  |  |  |  |  |
| 9:30 a.m.                  | Case Resolution, Practice changes, Anticipated Studies/Future Directions             |  |  |  |  |  |  |  |
|                            | Javier L. Munoz, M.D., M.B.A.  |  |  |  |  |  |  |  |
|                            | Primary and Secondary CNS Lymphoma   |  |  |  |  |  |  |  |
| 9:45 a.m.                  | Tumor Board Style Case   |  |  |  |  |  |  |  |
|                            | Early Career Investigator, Radiation Oncologist, Radiologist, William G. Breen, M.D. |  |  |  |  |  |  |  |
|                            | Current Disease Landscape  |  |  |  |  |  |  |  |
|                            | Early Career Investigator  |  |  |  |  |  |  |  |
| 10:00 a.m.                 | Key Studies From 18-ICML   |  |  |  |  |  |  |  |
|                            | Patrick Johnston, M.D., Ph.D.  |  |  |  |  |  |  |  |
| 10:15 a.m.                 | Panel Discussion   |  |  |  |  |  |  |  |
|                            | Patrick Johnston, M.D., Ph.D. Early Career Investigator, William G. Breen, M.D.      |  |  |  |  |  |  |  |
| 10:30 a.m.                 | Case Resolution, Practice changes, Anticipated Studies/Future Directions             |  |  |  |  |  |  |  |
| 10:45 a.m.                 | Break / Open Discussion  |  |  |  |  |  |  |  |
|                            | Mechanisms of Resistance   |  |  |  |  |  |  |  |
| 11:00 a.m.                 | To Small Molecules   |  |  |  |  |  |  |  |
| 11:30                      | To CAR T-cell therapy  |  |  |  |  |  |  |  |
|                            | Saad J. Kenderian, M.B.Ch.B.   |  |  |  |  |  |  |  |
| 1:00 p.m.                  | Closing Remarks  |  |  |  |  |  |  |  |
|                            | Grzegorz S. Nowakowski, M.D., Emanuele Zucca, M.D.                                   |  |  |  |  |  |  |  |



#### **Request for Taxpayer Identification Number and Certification**

Go to www.irs.gov/FormW9 for instructions and the latest information.

Give form to the requester. Do not send to the IRS.

| Befor  | e yo   | <b>bu begin.</b> For guidance related to the purpose of Form W-9, see <i>Purpose of Form</i> , below.   |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
|--|--|---|------------|-------|---------|--------------------------|----------------|---|---|-------------------|---------|---------|--|--|--|--|
|  | 1  | Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the orentity's name on line 2.)  | wner's nar | me d  | on line | 1, an                    | d e            | nter th   | e bus   | ines              | ss/disr | egarded |  |  |  |  |
|  | Ма   | Mayo Clinic   |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
|  | 2 Business name/disregarded entity name, if different from above.  |   |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
| Print or type. Specific Instructions on page 3.  | 3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only one of the following seven boxes.  □ Individual/sole proprietor □ C corporation □ S corporation □ Partnership □ Trust/estate □ LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) .  Note: Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner.  ✓ Other (see instructions)  501 (c) (3) Tax-exempt Nonprofit Corporation |   |            |       |         |                          |                | 4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3):  Exempt payee code (if any)  Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any)  A |   |                   |         |         |  |  |  |  |
| P<br>Specific  | 3b   | 3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions |            |       |         |                          |                |   | (Applies to accounts maintained outside the United States.) |                   |         |         |  |  |  |  |
| See  | 5  | 5 Address (number, street, and apt. or suite no.). See instructions. Requester's name   |            |       |         |                          |                | and address (optional)  |   |                   |         |         |  |  |  |  |
| 0,   | 200  | 200 First Street SW   |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
|  | 6 City, state, and ZIP code  |   |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
|  | Ro   | Rochester, MN 55905   |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
|  | 7  | List account number(s) here (optional)  |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
| Par  | tΙ   | Taxpayer Identification Number (TIN)  |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |
| ` '  |  |   |            |       |         |                          | ecurity number |   |   |                   |         |         |  |  |  |  |
| backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see <i>How to get a</i> |  |   |            |       | - [     |                          | ]-             |   |   |                   |         |         |  |  |  |  |
| TIN. later.  |  |   |            |       |         | er identification number |                |   |   |                   |         |         |  |  |  |  |
| Note: If the account is in more than one name, see the instructions for line 1. See also What Name and   |  |   |            |       |         |                          |                |   |   | $\overline{\Box}$ |         |         |  |  |  |  |
| Vumb   | er T   | o Give the Requester for guidelines on whose number to enter.   |            | 4     | 1       | -   6                    | 6              | 0   1   | 1   | 7                 | 0       | 2       |  |  |  |  |
| Par  | t II   | Certification   | ·          |       | '       |                          |                |   |   | •                 |         | •       |  |  |  |  |
| Unde   | pe   | nalties of perjury, I certify that:   |            |       | _       |                          | _              |   |   | _                 |         |         |  |  |  |  |
| 2. I ar  | n no   | mber shown on this form is my correct taxpayer identification number (or I am waiting for a subject to backup withholding because (a) I am exempt from backup withholding, or (b)   | I have no  | ot be | een r   | otifie                   | d b            | y the   | Inter   |                   |         |         |  |  |  |  |
| Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and  |  |   |            |       |         |                          |                |   |   |                   |         |         |  |  |  |  |

- no longer subject to backup withholding; and
- 3. I am a U.S. citizen or other U.S. person (defined below); and
- 4. The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Signature of 01/02/2025 Saty Domaille Here U.S. person Date

Cat. No. 10231X

# General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

Future developments. For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/FormW9.

#### What's New

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

#### Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they